[Hodgkin's lymphoma].
During the past 2 decades, major medical advances have resulted in dramatic improvements in cure rates for the majority of children with cancer, including those with Hodgkin's disease. Long-term data from different Institutions reveal actuarial 5, 10 and 15 year survival rates of 90, 80 and 70% and corresponding freedom from relapse rates of 75, 66 and 66% respectively. The prices that are paid to achieve these results are high in term of growth and development, sterility and second malignant tumor. The present challenge in the treatment of children with Hodgkin's disease is to delineate a therapeutic program which will insure continuation of the excellent survival and disease-free survival which are now being achieved while minimizing the risks of complications from treatment. At present it appears that the combination of low dose irradiation and chemotherapy (alternating non-cross-resistant drug combinations: MOPP/ABVD) is successful in affording optimistic cure rate with minimal morbidity. However, there are many questions which require a specific answer in the future: to define the risk/benefit ratio of therapy and to establish the role of surgical staging in the pediatric population.